Here, we evaluate pragmatic clinical outcomes among a cohort of younger low-risk patients with low ODX RS (ages 50 to 69 years with T1N0, hormone receptor–positive, ERBB2 [formerly HER2]-negative breast cancer and ODX RS 18) who received various permutations of adjuvant RT and ET. Here, ERBB2 is linked to breast carcinoma.